Ultimately, lowering levels of mutant Huntingtin in HD settings is the most widely accepted therapeutic strategy and here it would be useful to have a set of biomarkers for both central and peripheral (e.g., skeletal muscle) pathology. Here, HTT is linked to Huntington disease.